STOCK TITAN

Virpax Pharmaceuticals, Inc. - VRPX STOCK NEWS

Welcome to our dedicated page for Virpax Pharmaceuticals news (Ticker: VRPX), a resource for investors and traders seeking the latest updates and insights on Virpax Pharmaceuticals stock.

Virpax Pharmaceuticals, Inc. (symbol: VRPX) is a pioneering biopharmaceutical company dedicated to developing advanced drug delivery systems aimed at improving patient compliance and achieving therapeutic efficacy. Specializing in non-opioid pain management, Virpax is committed to enhancing patients' quality of life through innovative pharmaceutical products.

As a preclinical stage company, Virpax focuses on creating branded pharmaceutical products for pain management. Their impressive product portfolio includes:

  • Topical Metered-Dose Spray: A novel approach for localized pain relief.
  • Liposomal in Hydrogel Encapsulation: A cutting-edge technology designed to enhance drug delivery and efficacy.
  • Enkephalin Intranasal Spray: An innovative treatment method aimed at providing rapid pain relief.

Virpax Pharmaceuticals collaborates with a network of U.S. and global partners to advance the development of its proprietary drug platforms. Their goal is to become a global leader in non-opioid pain management, creating value for investors and partners alike.

Recent achievements and current projects highlight Virpax’s commitment to innovation. These include advancing their drug candidates through preclinical stages, securing strategic partnerships, and working towards regulatory approvals.

Financially, Virpax Pharmaceuticals is focused on sustainable growth, leveraging cutting-edge technology to develop products that meet the unmet needs of pain management patients. The company’s strategic initiatives are designed to enhance shareholder value while pushing the boundaries of pharmaceutical advancements.

Stay tuned for the latest updates and exciting developments from Virpax Pharmaceuticals as they continue to make strides in the biopharmaceutical industry.

Rhea-AI Summary

Virpax Pharmaceuticals announced positive results from a Swine Model pilot study for Probudur, their long-acting pain relief formulation. Probudur, designed for extended pain relief, was tested on four juvenile pigs at 30 mg/kg. The study confirmed a long-term, slow-release profile and showed that Probudur was well-tolerated with no adverse effects. Histopathology at the injection site also indicated good tolerance. CEO Gerald Bruce highlighted the consistent positive results and the aim to file an Investigational New Drug Application by year-end. Probudur aims to reduce opioid use post-surgery by providing prolonged pain relief.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
46.55%
Tags
none
-
Rhea-AI Summary

Virpax Pharmaceuticals announced securing a $2.5 million loan from an institutional investor, which facilitated the final payment of its litigation settlement. This loan agreement includes negotiating additional funding to support the development of non-addictive pain management and CNS disorder products.

The company's Board of Directors has been reorganized, reducing its members from eight to seven. Four new members—Judy Su, Gary Herman, Jatinder Dhaliwal, and Katharyn Field—have been appointed, while five existing members have resigned.

CEO Gerald Bruce emphasized that this funding will provide the flexibility needed to advance their programs, with the goal of beginning first-in-human trials in 2025. The announcement follows high interest in Virpax's asset portfolio at the recent BIO meeting in San Diego.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
92.04%
Tags
none
-
Rhea-AI Summary

Virpax Pharmaceuticals (NASDAQ: VRPX), a firm developing non-addictive treatments for pain, PTSD, CNS disorders, and viral barriers, will present at the 2024 BIO International Convention in San Diego. CEO Gerald W. Bruce will deliver a corporate presentation on June 3rd at 4:00 p.m. PT in Theater 3. The Virpax team will also host meetings from June 3rd through the 5th. Interested parties can schedule meetings via the BIO International meeting platform or by contacting betsy.brod@affinitygrowth.com.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.67%
Tags
conferences
Rhea-AI Summary

Virpax Pharmaceuticals announced the pricing of a public offering totaling $2.25 million. This offering includes 1,666,667 shares of common stock and Series A-1 and A-2 warrants. The shares and warrants are priced at $1.35 each, with Series A-1 warrants expiring in five years and Series A-2 in eighteen months. The offering is expected to close around May 17, 2024, subject to customary conditions. The securities are being offered under a registration statement filed with the SEC.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-65.94%
Tags
-
Rhea-AI Summary

Virpax Pharmaceuticals (NASDAQ: VRPX) announced its Q1 2024 results and recent developments. The company reported an increase in general and administrative expenses to $1.7M and R&D expenses to $1.6M, leading to an operating loss of $3.2M. Cash reserves stood at $1.9M as of March 31, 2024. Key highlights include the positive results of the Probudur™ Maximum Tolerated Dose Study, ongoing development of Envelta™ and NobrXiol™, and a settlement agreement with Sorrento Therapeutics and Scilex Pharmaceuticals. The company is also seeking additional grants and licensing opportunities. CEO Gerald W. Bruce expressed optimism about the future despite the financial challenges.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-24.67%
Tags
-
Rhea-AI Summary

Virpax Pharmaceuticals, Inc. announced the results of a Maximum Tolerated Dose (MTD) study for Probudur™, a long-acting liposomal bupivacaine formulation aimed at reducing the need for opioids after surgery. The study showed that Probudur provided both immediate and sustained pain relief at the wound site, with minimal toxicity and better therapeutic results compared to free bupivacaine. The formulation demonstrated the potential to offer rapid onset and prolonged action, marking significant progress towards completing preclinical studies and filing for an Investigational New Drug Application (IND) by the end of the year.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.33%
Tags
none
Rhea-AI Summary
Virpax Pharmaceuticals, Inc. announced its financial results for the twelve months ended December 31, 2023, highlighting regained compliance with Nasdaq, settlement agreements, and progress in developing non-addictive pain management products. The company reported positive initial results from a pilot study of Probudur™ by the U.S. Army Institute of Surgical Research, with plans for further studies. Virpax also emphasized its focus on non-addictive product candidates, government grants, and partnerships to advance pain assets.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.94%
Tags
none
-
Rhea-AI Summary
Virpax Pharmaceuticals, Inc. announced a 1-for-10 reverse stock split of its common stock, aiming to regain Nasdaq compliance and attract more investors. The split will reduce outstanding shares from 11.7 million to 1.2 million, with no change in ownership percentage. The company's CEO expressed optimism about future prospects despite challenges in the capital markets.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-14.71%
Tags
-
Rhea-AI Summary
Virpax Pharmaceuticals, Inc. has entered into a term sheet to settle litigation with Sorrento Therapeutics, Inc. and Scilex Pharmaceuticals, Inc. The settlement includes cash payments totaling $6 million and royalties on net sales of certain products.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-14.71%
Tags
none
Rhea-AI Summary
Virpax Pharmaceuticals, Inc. announced positive initial results from a pilot study for Probudur, a product designed to reduce or eliminate the need for opioids after surgery or trauma. The study, performed by the U.S. Army Institute of Surgical Research, showed that both doses of Probudur reduced incision-induced pain behaviors in a rat model. Virpax has also highlighted its success in securing government grants to fund clinical trials for its products.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.97%
Tags
none

FAQ

What does Virpax Pharmaceuticals, Inc. specialize in?

Virpax specializes in developing advanced drug delivery systems for pain management, focusing on non-opioid therapies.

What are some of Virpax Pharmaceuticals' key products?

Key products include a topical metered-dose spray, liposomal in hydrogel encapsulation, and an enkephalin intranasal spray.

Is Virpax Pharmaceuticals a preclinical stage company?

Yes, Virpax Pharmaceuticals is currently a preclinical stage biopharmaceutical company.

What is Virpax's goal in the pharmaceutical industry?

Virpax aims to become a global leader in non-opioid pain management by developing innovative pharmaceutical products.

How does Virpax enhance the efficacy of its products?

Virpax uses cutting-edge technology in its drug delivery systems to improve patient compliance and therapeutic efficacy.

Who does Virpax collaborate with for its developments?

Virpax collaborates with a network of U.S. and global partners to advance its proprietary drug platforms.

What type of spray is included in Virpax's product portfolio?

Virpax's product portfolio includes a topical metered-dose spray and an enkephalin intranasal spray.

How is Virpax Pharmaceuticals enhancing shareholder value?

Virpax focuses on sustainable growth and strategic initiatives to enhance shareholder value while advancing pharmaceutical innovations.

What technology does Virpax use for drug encapsulation?

Virpax uses liposomal in hydrogel encapsulation technology for enhanced drug delivery and efficacy.

Where can I find the latest news about Virpax Pharmaceuticals?

The latest news and updates on Virpax Pharmaceuticals can be found on financial news websites and the company's official announcements.

Virpax Pharmaceuticals, Inc.

Nasdaq:VRPX

VRPX Rankings

VRPX Stock Data

2.93M
2.84M
10.99%
0.07%
1.04%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
BERWYN